Abstract
Small interfering RNA (siRNA) has been demonstrated to be a powerful tool for silencing post-transcriptional gene expression, and thus exhibits great potential in cancer gene therapy. However, siRNA technology has not become an established strategy for cancer treatment, as it is a considerable challenge to deliver siRNA to the targeting sites. In this review, barricades in the systemic delivery of siRNA were systematically introduced, from pharmacokinetics, biodistribution and intracellular behavior. Meanwhile, current and potential strategies for overcoming the barricades were elucidated, including chemical modification of siRNA, nanomaterial-based delivery systems, and targeting and stimuli-responsive smart carriers. In conclusion, the siRNA-based gene silencing drug will gain an important position for treating human diseases if we can solve the gap between ideal and reality.
Keywords: siRNA, gene silencing, barricade, delivery system, smart carrier.
Current Pharmaceutical Biotechnology
Title:Ideal and Reality: Barricade in the Delivery of Small Interfering RNA for Cancer Therapy
Volume: 17 Issue: 3
Author(s): Di Wu, Haobo Han, Zhen Xing, Jianxu Zhang, Li Li, Wei Shi and Quanshun Li
Affiliation:
Keywords: siRNA, gene silencing, barricade, delivery system, smart carrier.
Abstract: Small interfering RNA (siRNA) has been demonstrated to be a powerful tool for silencing post-transcriptional gene expression, and thus exhibits great potential in cancer gene therapy. However, siRNA technology has not become an established strategy for cancer treatment, as it is a considerable challenge to deliver siRNA to the targeting sites. In this review, barricades in the systemic delivery of siRNA were systematically introduced, from pharmacokinetics, biodistribution and intracellular behavior. Meanwhile, current and potential strategies for overcoming the barricades were elucidated, including chemical modification of siRNA, nanomaterial-based delivery systems, and targeting and stimuli-responsive smart carriers. In conclusion, the siRNA-based gene silencing drug will gain an important position for treating human diseases if we can solve the gap between ideal and reality.
Export Options
About this article
Cite this article as:
Wu Di, Han Haobo, Xing Zhen, Zhang Jianxu, Li Li, Shi Wei and Li Quanshun, Ideal and Reality: Barricade in the Delivery of Small Interfering RNA for Cancer Therapy, Current Pharmaceutical Biotechnology 2016; 17 (3) . https://dx.doi.org/10.2174/1389201017666151029110710
DOI https://dx.doi.org/10.2174/1389201017666151029110710 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Current Pharmaceutical Design Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Letters in Drug Design & Discovery Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
Current Topics in Medicinal Chemistry The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Designing of Novel Carbonic Anhydrase Inhibitors and Activators
Current Medicinal Chemistry - Cardiovascular & Hematological Agents HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Sera/Organ Lysates of Selected Animals Living in Polluted Environments Exhibit Cytotoxicity against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Recent Advances in Vaccine Delivery)
Current Drug Therapy Antibody-Based Imaging of HER-2: Moving into the Clinic
Current Molecular Medicine Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Inorganic Nanoparticles for Enhanced Photodynamic Cancer Therapy
Current Drug Discovery Technologies Brain Tumor-Related Epilepsy
Current Neuropharmacology Precise Analysis of the Autofluorescence Characteristics of Rat Colon Under UVA and Violet Light Excitation
Current Pharmaceutical Biotechnology Adolescent Girls and their Mothers’ Knowledge and Opinions about Human Papilloma Virus Vaccine
Current Women`s Health Reviews Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects
Current Medicinal Chemistry Targeting miRNAs for Pancreatic Cancer Therapy
Current Pharmaceutical Design MicroRNA Polymorphisms, MicroRNA Pharmacogenomics and Cancer Susceptibility
Current Pharmacogenomics and Personalized Medicine Intranasal Drug Delivery for Brain Targeting
Current Drug Delivery Novel 2-Thienyl- and 2-Benzothienyl-Substituted 6-(2-Imidazolinyl)Benzothiazoles: Synthesis; in vitro Evaluation of Antitumor Effects and Assessment of Mitochondrial Toxicity
Anti-Cancer Agents in Medicinal Chemistry Design and Synthesis of Curcumin-Like Diarylpentanoid Analogues as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery